CLINICAL_TRIALS
trial_result
· 2025-02-10
Clinical Trial Update: NB-001 in Children and Adolescents With 22q11 Deletion Syndrome [Phase 2]
Summary
NB-001 has completed a Phase 2 trial in children and adolescents with 22q11.2 deletion syndrome, and the results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Nobias Therapeutics, Inc. | Conditions: 22q11 Deletion Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2025-02-10